The reagents' magnetic bead-based, automated method extracts and isolates virus particles and their respective RNA on many open platforms for subsequent real-time RT-PCR (reverse transcription polymerase chain reaction) analysis using approved IVD kits.
GSD NovaPrime RNA Extraction AE1 and AE2 kits are validated for use with KingFisher Flex and MGI MGISP-960 automation platforms.
Compatibility testing with several other open-platform extraction instruments is underway.
The kits are ideal for use with the GSD NovaPrime SARS-CoV-2 (COVID-19) RT-PCR clinical IVD assay for virus detection.
The kits have to be validated as required by local legislation for their intended use by authorized clinical testing laboratories.
A CE-IVD marked version of the kit will be released at a later stage.
As COVID-19 continues to accelerate worldwide, diagnostic laboratories face an unprecedented demand for testing capacity.
Eurofins' introduction of the GSD NovaPrime RNA Extraction kits positions laboratories to meet this demand with an easy and highly efficient extraction method that works with a large range of existing automation equipment.
Eurofins GeneScan Technologies, a proven leader in bio-molecular testing committed to the highest quality standards and technical excellence for more than 25 years, developed the assays.
Eurofins is in food, environmental, pharmaceutical and cosmetics products testing and in agroscience CRO services.
It is in testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences and in esoteric and molecular clinical diagnostic testing.
With over 47,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins' companies offer a portfolio of over 200,000 analytical methods.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review